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Abstract
Eya1 is a conserved critical regulator of organ-specific stem cells. Ectopic Eya1 activities, 
however, promote transformation of mammary epithelial cells. Signals that instigate Eya1 
oncogenic activities remain to be determined. Here, we show that Akt1 kinase physically interacts 
with Eya1 and phosphorylates a conserved consensus site of the Akt kinase. PI3K/Akt signaling 
enhances Eya1 transcription activity, which largely attributes to the phosphorylation-induced 
reduction of Eya1 SUMOylation. Indeed, SUMOylation inhibits Eya1 transcription activity; and 
pharmacologic and genetic activation of PI3K/Akt robustly reduces Eya1 SUMOylation. Wild 
type but not Akt phosphorylation site mutant Eya1 variant rescues the cell migratory phenotype of 
EYA1-silenced breast cancer cells, highlighting the importance of Eya1 phosphorylation. 
Furthermore, knockdown EYA1 sensitizes breast cancer cells to the PI3K/Akt1 inhibitor and 
irradiation treatments. Thus, the PI3K/Akt signal pathway activates Eya1. These findings further 
suggest that regulation of SUMOylation by PI3K/Akt signaling is likely an important aspect of 
tumorigenesis.
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Introduction
Eyes absent 1 (Eya1) is a transcriptional coactivator that has intrinsic protein phosphatase 
activity.1–5 Among four Eya-family genes, Eya1 is essential for proliferation and survival of 
organ-specific progenitors such as renal and cardiac progenitors.6, 7 Human EYA1 
haploinsufficiency causes branchio-oto-renal (BOR) birth defect.7 Under pathological 
conditions, ectopic EYA1 activity is linked to oncogenic transformation of mammary 
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epithelial cells and breast cancer progression.8, 9 Signals that instigate Eya1 oncogenic 
activities are unknown.
Eya1 functions as a canonical transcription coactivator of Six1 homeodomain transcription 
factor.1, 10, 11 The Six1-Eya1 transcription complex regulates expression of a number of 
downstream target genes that are important for cell proliferation, survival and migration. For 
instance, c-Myc expression is dramatically diminished in Six1 null mutant embryos.1 Ectopic 
Six1 expression promotes tumorigenesis by stimulating expression of Cyclin A1.12 Cyclin 
D1 is also regulated by the Six1-Eya1 transcription complex.13, 14 The intrinsic Eya1 
phosphatase activity is in part required to regulate Cyclin D1 gene expression.14 Six1 also 
increases TGFβ signaling and promotes epithelial-mesenchymal transition (EMT) and 
metastasis of human mammary carcinoma cells.15 In addition to transcription activities of 
Eya-family proteins, enzymatic activity of Eya2 and Eya3 controls cytoskeletal 
organization, and enhance breast cancer cell migration and metastasis independent.8 
Upregulation of human SIX1 is linked to advanced stages of breast cancer.13, 15–17 
Furthermore, breast cancers with high levels of both EYA (1 or 2) and SIX1 have poor 
prognosis, including shortened time to relapse, progression to metastasis, and decreased 
survival rates.9 Given the critical role of Eya-family proteins in regulating cellular behavior 
and organ development, it is not surprising that aberrant activity of these genes may result in 
cancers. However, it does raise an important question on how Eya1 protein activity is 
regulated during cancer development.
Eya1 is post-translational modified by the small ubiquitin-related modifier 1 (SUMO1) 
protein (SUMOylation) but the potential role of Eya1 SUMOylation is largely unknown.18 
Genetic polymorphisms in the SUMO-conjugating enzymes UBC9 and PIAS3 are 
associated with increased breast cancer grade and reduced DNA-damage repair 
responses.19–21 UBC9 is aberrantly overexpressed in luminal type of breast cancers.22 
Differential expression of SUMO-specific protease 7 (SENP7) isoforms in breast cancer 
cells regulates tumor progression.23 Thus, losing the balance between substrate 
SUMOylation and de-SUMOylstion may be involved in Eya1 regulation during cancer 
development.
The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node of 
the phosphatidylinositol 3-kinase (PI3K) signal pathway. PI3K/AKT signaling is frequently 
hyperactivated in human cancers, including breast cancers.24–26 In this study, we show that 
PI3K/Akt signaling enhances transcription activity of Eya1 via repressing its SUMOylation. 
EYA1 is required for proliferation and migration of a subset of the aggressive triple-negative 
breast cancer (TNBC) cells. PI3K/Akt signaling represses Eya1 SUMOylation thereby 
promotes Eya1 oncogenic activity in a phosphorylation-dependent manner. Moreover, 
genetic silencing of EYA1 significantly increases sensitivity of breast cancer cells to PI3K/
Akt1 inhibition and irradiation treatments. Together, results from this study suggest that the 
PI3K/Akt-mediated repression of substrate SUMOylation, such as Eya1, is an important new 
aspect of cancer biology.
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Results
Eya1 physically interacts with Akt1
An Akt-substrate consensus motif was identified in Eya1 protein sequence from sea urchin 
to human (Figure 1A). This high degree sequence conservation suggested that the PI3K/Akt 
signal pathway is a candidate upstream regulator of Eya1. To test this possibility, we first 
investigated protein-protein interaction between Akt1 and Eya1 (Figure 1B–E, S1). 
Endogenous EYA1 was detected in the AKT immunocomplex from human BT549 breast 
cancer cells (Figure 1B). Conversely, AKT was also detected from the EYA1 protein 
complex (Figure 1C), indicating an association between these proteins. To further 
characterize potential interaction domain(s), a series of murine Flag-tagged Eya1 (Flag/
Eya1) truncation mutations was created (Figures 1D, E and Figure S1). These variants were 
co-expressed with wild type murine Akt1 in HEK293 cells, and their interactions were 
assessed following immunoprecipitation with an Akt1 (Figure 1D) or a Flag-specific 
antibody (Figure S1). We observed a strong interaction between Akt1 and full-length Eya1 
(Figure 1D and S1). Eya1 fragment A containing amino acids 1–497 (aa1-497) was unstable 
thus precluding a reliable evaluation (Figure 1D and S1). Fragment B (aa1-326) was highly 
expressed yet no interaction with Akt1 was detected. In contrast, both fragment C 
(aa316-497) and D (aa316-591) interacted strongly with Akt1. Thus, Akt1 associates with 
the evolutionarily conserved C-terminal Eya-phosphatase domain.
To examine whether Eya1 was a substrate of Akt kinase, immunopurified wild type and 
S298A mutant Eya1 proteins were incubated with a recombinant active AKT1 kinase 
and 32P-gamma ATP in an in vitro kinase reaction (Figure 1F). Wild type Eya1 was labeled 
in the IP-kinase reaction. However, mutation of S298 to alanine (S298A), which rendered it 
incompatible to phosphorylation, was not phosphorylated by AKT1. To study whether this 
site could be phosphorylated in vivo, we used a phospho-(Ser/Thr) Akt substrate (p-sub) 
antibody to evaluate Eya1 phosphorylation status. This antibody recognizes a large number 
of phosphorylated Akt substrates since it preferentially binds to proteins containing 
phospho-Ser/Thr preceded by Lys/Arg at positions −5 and −3; and the antibody-binding 
specificity is largely independent of other surrounding sequences.27 Flag/Eya1 was detected 
by the p-sub antibody (Figure 1G, lane 1 of the top panel). Coexpression of a constitutively 
active Akt1, which is myristoylated and HA-tagged (myr-HA/Akt1), increased signal of the 
p-sub immunoreactivity (Figure 1G, compare lane 1 to lane 2, top panel). S298A variant had 
markedly decreased signal (Figure 1G, compare lane 2 to lane 3, top panel). Together, these 
observations suggest that S298 is phosphorylated, and activation of Akt1 kinase increases 
S298 phosphorylation level.
We also noted that the Eya1(S298A) mutant variant remained reactive to the p-sub antibody 
(Figure 1G, lane 3, top panel). It is therefore possible that endogenous Eya1 could be 
phosphorylated at multiple sites in addition to S298.
Akt1 enhances Eya1 transcription activity
Eya1 is the canonical co-activator of the homeodomain transcription factor Six1. Six1 binds 
to Eya1 and induces Eya1 translocation from the cytoplasm to the nucleus where the Six1/
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Eya1 transcription complex activates target gene expression.11 To examine whether Akt1 
regulated Eya1 function, we initially examined whether Akt1 influenced Eya1 localization. 
As shown in Figure 2A, full length Eya1 localized to both cytoplasm and nucleus in the 
presence of active myr-HA/Akt1 (Figure 2A), which is similar to Eya1 localization pattern 
in normal HEK293.11 Therefore, Akt1 has no obvious influence on the overall localization 
pattern of Eya1.
We next investigated whether Akt1 was directly associated with the Six1/Eya1 transcription 
complex. Combinations of wild type Akt1, Flag/Eya1 and Myc-tagged Six1 (Myc/Six1) 
were co-expressed in HEK293 cells, and immunocomplex were interrogated for the 
presence of prospective components (Figures 2B and C). Unlike Flag/Eya1, Myc/Six1 was 
not detected in Akt1 immunocomplex with or without Flag/Eya1 (Figure 2B, the second 
panel). Instead, co-expression of Myc/Six1 slightly reduced the interaction between Flag/
Eya1 and Akt1 (Figure 2B, comparing lanes 2 and 3 of the first panel). A similar 
phenomenon was observed when the Flag/Eya1 immunocomplex was examined, from which 
less Akt1 was detected when Myc/Six1 was co-expressed (Figure 2C, compare lanes 2 and 3 
of the third panel). Flag/Eya1 interacted with Myc/Six1 with or without co-expression of 
Akt1 (Figure 2C, the second panel). Thus, Akt1 is unlikely to be a component of the Six1/
Eya1 transcription complex.
To determine whether Akt1 is capable of regulating Eya1 transcription activity, we 
performed a transcription reporter assay using a Six1-binding element-dependent luciferase 
reporter (SE1/luc).1, 7 The reporter itself had minimal basal activity in HEK293 cells, and 
coexpression of both Eya1 and Six1 resulted in a significant increase of the reporter activity 
(Figure 2D). Mutation of the phosphorylation site (S298A) significantly reduced Eya1 
transcription activity. A constitutively active myr-HA/Akt1 further enhanced reporter 
activity mediated by wild type Eya1 but not S298A mutant. MKK6 is a known activator of 
the Six1/Eya1 transcription reporter.28 The effect of MKK6 was not impaired by the S298A 
mutation. Thus, activation of Akt1 induces Eya1 transcription activity (Figure 2E), and this 
in part depends on the conserved S298 residue at the Akt-substrate consensus motif.
Functional interaction between Akt1 and Eya1 in vivo
Eya1 is a critical regulator of kidney development and kidney size formation is particularly 
sensitive to levels of Eya1 activity29. Akt1 is a central regulator of cell proliferation and 
survival; and is required for growth of all organs including kidney1, 6, 30, 31. To investigate 
whether Akt1 functionally interacts with Eya1 in vivo, we therefore analyzed the kidney size 
of compound Akt1−/− and Eya1+/− mutants (Figure S2). The overall body size of newborn 
Akt1-null mutants was approximately 25% smaller than littermate controls (Figure S2B, 
n=6), confirming its critical roles in growth and cell proliferation30, 31. The kidney to body 
weight ratio of Akt1−/− mutants, however, was comparable to that of controls (Figure S2B, F 
and I), consistent with the finding that Akt1 mutant is proportionally smaller, owing to the 
global reduction of cell number32. Eya1+/− were grossly normal (Figure S2C, n=9). 
Compound Akt1−/−;Eya1+/− mutants exhibited overall body sizes comparable to Akt1−/− 
mutants. Notably, kidneys were significantly smaller in these compound mutants than 
Akt1−/− or Eya1+/− single mutants, as indicated by a reduced kidney to body weight ratio 
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(Figure S2D, H and I, n=18). Thus, consistent with biochemical observations (Figure 1 and 
2), these genetic findings support a functional interaction between Akt1 and Eya1 in vivo.
Eya1 is post-translational modified by SUMO protein
We next wished to understand how PI3K/Akt signaling regulated Eya1 transcription 
activity. Because of the critical role of SUMOylation in transcription repression;33–37 and 
Eya1 is a SUMOylated protein,18 we focused on a SUMOylation-dependent mechanism.
The precise nature of Eya1 SUMOylation and how SUMOylation regulates Eya1 
transcription activity remain to be determined. To confirm that Eya1 is indeed SUMOylated, 
immunopurified endogenous EYA1 proteins were examined using a SUMO1-specific 
antibody (Figure 3A). Several slow migrating high molecular weight bands were detected, 
which likely corresponded to SUMOylated EYA1 (Figure 3A). Conversely, examination of 
SUMO1 immunocomplex using an EYA1 antibody also detected similar high molecular 
bands (Figure 3B). To ascertain that these slow migration bands were indeed SUMOylated 
Eya1, Flag/Eya1 and HA-tagged Sumo1 (HA/Sumo1) were coexpressed in HEK293 cells, 
and SUMOylation pattern of Flag/Eya1 was examined using a HA-specific antibody (the 
first lanes in Figure 3C and D). We detected three high molecular weight bands, which 
corresponded to mono- and di-SUMOylation as they had a characteristic incremental size 
increase of HA/Sumo1 moiety (~12 kDa). Indeed, coexpression of SenP2, a SUMO-specific 
peptidase, completely eliminated these slow migrating bands (Figure 3C).
Eya1 SUMOylation pattern suggested that it was modified at two possible sites. In addition 
to K43 and K459, sequence analysis revealed another SUMOylation site, K146. To pinpoint 
which of these three residues were SUMOylated, we generated a series of single, double and 
triple lysine-to-arginine (K/R) mutations to eliminate SUMOylation on these perspective 
sites. Wild type Flag/Eya1 immunocomplex exhibited a typical Eya1 SUMOylation pattern, 
a doublet of mono-SUMOylated and a single di-SUMOylated Eya1 variant (Figure 3D, first 
lane). K43R and K146R mutants displayed a mono SUMOylation pattern, while K459R 
showed a similar SUMOylation pattern to wild type control although the overall 
SUMOylation level was slightly lower than wild type. Mutation of both K43 and K459 
residues (K43/459R) had mono-SUMOylation, which was similar to the SUMOylation 
pattern to K43R variant. In addition, K146/459R and K146R mutants exhibited a similar 
mono-SUMOylation pattern. Importantly, K43/146R and K43/146/459R mutants were not 
SUMOylated. Together, these systematic mutagenesis analyses indicate that Eya1 K43 and 
K146 but not K459 are SUMOylated.
SUMOylation represses Eya1 transcription activity
To determine potential impact of SUMOylation on Eya1 transcription activity, we used both 
SE1/luc and a native Fgf8 (Fgf8/luc) reporter.1, 7 The de-SUMOylated Eya1 variants, 
K43/146R (2KR), exhibited a significantly higher transcriptional activity than wild type 
Eya1 (Figure 3E and S3), raising a possibility that SUMOylation inhibits Eya1 activity. In 
line with this observation, coexpression of SenP2, which reduced Eya1 SUMOylation 
(Figure 3C), significantly induced both SE1/luc and Fgf8/luc reporters (Figure 3F and S3B). 
We also created two fusion proteins, in which Sumo1 was positioned at either C-terminal 
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(Eya1-S1) or N-terminal (S1-Eya1) of Eya1 protein. Previous studies have shown that such 
fusion protein mimics SUMOylated substrate, particularly with regard to transcription 
regulators.37, 38 We found that fusion of Sumo1 significantly attenuated Eya1 transcription 
activities, consistent with the notion that SUMOylation represses Eya1 transcription activity 
(Figure 3G and S3C).
In parallel to reporter assays, endogenous Six1/Eya1 transcription targets were investigated 
using quantitative real-time PCR (Figure S3D). Consistent with reporter assays, wild type 
Eya1 significantly increased expression of its endogenous target, Fgf8.1, 7 In comparison, 
Eya1(K43/146R) mutant variant had a 55% increase of transcription activity than wild type 
Eya1 (Figure S3D). On the other hand, the hyper-SUMOylated S298A mutant was much 
less effective (Figure S3D). CYCLIN D1 and c-MYC are two additional Six1-Eya1 target 
genes.1, 13, 14 Similar to FGF8, de-SUMOylated K43/146R but not hyper-SUMOylated 
S298A variant significantly induced expression of these genes in HEK293 cells (Figure S3E 
and S3F). Together, both reporter and endogenous gene expression levels indicate that 
SUMOylation represses Eya1 transcription activity.
PI3K/Akt promotes transcription activity of Eya1 by repressing its SUMOylation
We next examined whether Akt1 regulated Eya1 through a SUMOylation mechanism. 
Firstly, we manipulated PI3K/AKT signaling using both siRNA and the 
phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002. To avoid potential compensatory 
effects among AKT isoforms, all isoforms were targeted by a mixture of siRNAs. Both 
LY294002 (Figure 4A and B) and siRNA knockdown (Figure 4C) strongly enhanced 
endogenous EYA1 (Figure 4A) and Flag/Eya1 (Figure 4B and C) SUMOylation levels in 
HEK293 cells. On the other hand, mutation of the Akt phosphorylation site, S298A, 
increased Eya1 SUMOylation (Figure 4D). Constitutively active myr-HA/Akt1 attenuated 
Eya1 SUMOylation in a dose-dependent manner (Figure 4E). However, it had minimal 
effect on the SUMOylation level of Eya1(S298A) mutant variant (Figure 4F). Thus, 
PI3K/Akt signaling inhibits Eya1 SUMOylation, and this inhibition is in part mediated by 
the conserved S298 phosphorylation site.
Secondly, we created a compound Eya1 mutant variant, KS/RA, which could not be 
SUMOylated (K43/146R) or phosphorylated (S298A) at these respective sites, to examine 
whether Eya1 phosphorylation functions independently to the SUMOylation pathway. 
Transcription activities of these mutant variants (K43/146R and KS/RA) were compared 
with or without myr-HA/Akt1. K43R/K146R had a robust transcription activity (Figure 4G). 
Addition of myr-HA/Akt1 did not further increase K43/146R transcription activity (Figure 
4F, compare bar 2 and 3). Transcription activity of Eya1(KS/RA) variant was similar to that 
of K43/146R; and effect of myr-HA/Akt1 was not significant (Figure 4G, compare bar 4 and 
5). Therefore, PI3K/Akt signaling induced Eya1 transcription activity is primarily mediated 
by the phosphorylation-dependent reduction of Eya1 SUMOylation.
PI3K/Akt signaling is required for stress-induced reduction of Eya1 SUMOylation
Eya1 is a critical regulator of genotoxic stress response.39 Coincidently, genotoxic stress 
activates Akt1, which in turn provides a pro-survival signal.40 We therefore investigated 
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whether PI3K/Akt signaling regulated Eya1 SUMOylation during the stress response. 
Gama-irradiation of HEK293 cells at doses between 5 and 40 Gy resulted in a biphasic 
activation of AKT, as indicated by AKT phospho-473 immunoreactivity (Figure S4, p-S473/
AKT). A similar response was observed using mouse embryonic fibroblasts.40 Coincident to 
AKT activation, Eya1 SUMOylation decreased after γ-irradiation in a dose-dependent 
manner (Figure 5A, lanes 1–4). Eya1 SUMOylation reached to its lowest levels within 1 
hour after irradiation (10Gy) and persisted at a low level. Inhibition of PI3K/Akt signaling 
using LY294002 increased Eya1 SUMOylation at each respective time point relative to that 
of the wild type control (Figure 5A and B). Intriguingly, Eya1 SUMOylation reached its 
lowest levels after 2–4 hours in the presence of LY294002, which was nearly a 2-hour delay 
when compared to irradiation induced SUMOylation reduction in the absence of the 
inhibitor. SUMOylation levels of Eya1(S298A) mutant were high and reached to the lowest 
level 1 hour after γ-irradiation (Figure 5A–C). Surprisingly, its hypo-SUMOylated state 
failed to persist, as S298A SUMOylated level increased at 2, 4 and 8 hours of post-
irradiation (Figure 5A and C).
To further examine the dynamics of Eya1 SUMOylation after cellular stress, we treated cells 
with camptothecin (CPT, 10µM, 30 minutes), a topoisomerase I inhibitor that induces DNA 
damage and apoptosis. CPT treatment dramatically reduced Eya1 SUMOylation level 
(Figure 5D). Silencing of all AKT isoforms by siRNA enhanced Eya1 SUMOylation 
(Figures 4C and 5E), and rendered Eya1 SUMOylation insensitive to CPT treatment (Figure 
5E). Taken together, these observations suggest that genotoxic stress represses Eya1 
SUMOylation in a PI3K/Akt-dependent manner; and phosphorylation of S298 is required to 
keep Eya1 at the hypo-SUMOylated state.
Akt1 and Eya1 synergistically regulate breast cancer cell survival and migration
We next wished to investigate the significance of the PI3K/Akt/Eya1 axis in breast cancer 
cells. Gene expression profile of more than 50 different breast cancer cell lines have been 
characterized and compared.41, 42 A number of triple negative breast cancer (TNBC) cell 
lines were among these that had abnormal high levels of EYA1 (Figure S5A). EYA1 
expression of four TNBC cell lines, MDA157, BT549, MDA-MB-231 and SUM149, were 
independently examined and confirmed using a real-time quantitative PCR assay (Figure 
S5B). MDA157 had the highest of and SUM149 had the lowest of EYA1 expression among 
four of these cell lines. To investigate a potential role of EYA1 in these TNBC cells, we 
generated and screened a total of 11 independent lentivirus-based shRNA vectors to target 
EYA1-specific sequences (Table S1). Among them, five shEYA1 vectors robustly attenuated 
Six1-Eya1-based reporter activity (shEYA1 1–5, Figure S5C), and significantly silenced 
endogenous EYA1 transcripts in MDA-MB-231 cells (Figure S5D).
Knockdown of EYA1 using four independent hairpins significantly attenuated BT549 cell 
growth (Figure 6A and B). Similarly, EYA1 knockdown significantly reduced the growth of 
three other TNBC cell lines (Figure 6C). We found that MDA157 cells were particularly 
sensitive to EYA1 level (Figure 6C), suggesting a possibility that they were addicted to high 
level of EYA1 expression.
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To examine a functional interaction between PI3K/Akt and EYA1 in these cells, we treated 
and compared survival rate of parental and EYA1-silenced derivative cells with LY294002 
inhibitor. MDA-MB-231 cells have relatively low basal level of the PI3K/Akt activity. On 
the other, BT549 cells have a defective Pten thereby have significantly elevated AKT 
activity.43 Despite the difference, both cell lines are insensitive to low dose of LY294002 
treatment.44 Indeed, suboptimal amount of the drug had no effect on survival of wild type 
parental BT549 cells (Figure 6D). However, EYA1 knockdown significantly sensitized these 
cells to drug inhibitions. The enhanced sensitivity was also observed in EYA1-silenced 
MDA-MB-231 cells (Figure S6A). Similarly, genotoxic stress induced by CPT treatment 
reduced cell survival of both parental cell lines in a dose dependent manner; and EYA1-
silenced cells were significantly more sensitive to CPT treatment (Figure 6E, S6B).
To ascertain the specificity of shRNA targeting constructs, wild type mouse Eya1 was used 
to rescue effects observed in EYA1-silenced cells. Expression of mouse Eya1, which was 
insensitive to human shEYA1 targeting vectors, effectively restored drug resistance to Eya1-
silenced cells to an extent comparable to that of wild type control cells (Figure 6F), 
confirming that the observed phenotype was EYA1-specific. Thus, high levels of EYA1 
confer to reduced sensitivity to and increased tolerance of breast cancer cells to PI3K/AKT 
inhibition and genotoxic stress.
BT549 cells are highly migratory, a hallmark of aggressiveness of invasive cancer cells 
(Figure 7A and B). Over-expression of wild type mouse Eya1 resulted in a 3-fold increase of 
cell migration than control cells (Figure 7A and B, compare 1 and 3, n=3, p=0.012). 
Conversely, silencing of endogenous EYA1 gene significantly reduced cell migration (Figure 
7A, compare 1 and 2, n=3, p<0.007). The cell migration defect was partially rescued by wild 
type mouse Eya1 (Figure 7A and B, compare 1 and 4).
Having established the genetic rescue system to assay Eya1 functions, we next aimed to 
investigate whether phosphorylation was required for endogenous EYA1. Pools of stable 
EYA1-silenced BT549 cells were established (Figure 7C). Several murine Eya1 variants 
were subsequently stably expressed in EYA1-silienced cells to examine their ability to rescue 
the cell migration defect. Wild type and S298A mutant Eya1 variant had a similar level of 
expression in these stable cell lines (Figure 7C). D327A phosphatase-dead mutant was also 
expressed but with relatively lower expression level. EYA1 knockdown resulted in more than 
a 70% reduction of cell migration (Figure 7D, n=3, p=0.001). Expression of wild type 
mouse Eya1 partially but significantly rescued the migration defect (Figure 7D, n=3, 
p=0.001). Phosphatase-dead D327A variant was unable to revert the defects, confirming a 
previous report suggesting that EYA1 phosphatase activity is required for cancer cell 
motility and invasiveness.8 Interestingly, mutation of Akt phosphorylation site, S298A, 
significantly attenuated its effectiveness to rescue the migration defect (n=3, p=0.02) (Figure 
7D). These results suggest that Eya1-dependent breast cancer motility partially depends on 
the conserved Akt substrate phosphorylation site, S298.
Sun et al. Page 8
Oncogene. Author manuscript; available in PMC 2015 November 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Discussion
In this study, we provide the first evidence suggesting a functional interaction between the 
PI3K/Akt signal pathway and Eya1 transcription coactivator. These findings further suggest 
that the PI3K/Akt-dependent regulation of substrate SUMOylation is an important aspect of 
tumorigenesis.
The PI3K/Akt/Eya1 axis in breast cancer
PI3K/Akt signaling is often hyperactivated in cancer cells and its hyperactivation promotes 
tumor progression. Our studies extend this notion by revealing a previously unknown role 
for the PI3K/Akt/Eya1 axis in breast cancer cell proliferation, migration and stress 
resistance. Several lines of evidence support the notion that the PI3K/Akt1 signal regulates 
Eya1. We show that Eya1 is a candidate substrate of Akt1 kinase (Figure 1); and 
phosphorylation of Eya1 by PI3K/Akt signaling enhances Eya1 transcription activity by 
inhibiting Eya1 SUMOylation (Figures 2 and 3). It is worth noting that genetic silencing of 
Eya1 significantly sensitizes breast cancer cells to pharmacological inhibition of PI3K/Akt 
signaling, suggesting that they may function together to regulate cancer cell behavior 
(Figure 6). Indeed, Akt1 and Eya1 synergistically regulate kidney growth in vivo (Figure 
S2); wild type but not the phosphorylation site mutant Eya1 variant is able to rescue a 
migration phenotype of EYA1-silienced breast cancer cells (Figure 7), indicating that 
phosphorylation is important for endogenous Eya1 functions.
A predicted phosphorylation site of Eya1 protein is S298, which is located at the highly 
conserved Akt substrate consensus motif (Figure 1). We show that mutation of this site 
(S298A) significantly diminished IP-kinase labeling and phospho-specific immunoreactivity 
(Figure 1). Eya1(S298A) variant becomes insensitive to PI3K/Akt signaling with regard to 
Eya1 transcription activity (Figure 2) and SUMOylation level (Figure 4); and S298A is 
unable to substitute wild type Eya1 function in a genetic rescue experiment (Figure 7). 
Furthermore, our findings suggest that S298 is required to keep Eya1 at hypo-SUMOylated 
state (Figure 5). We also noted that in addition to S298, Eya1 might have other Akt 
phosphorylation sites, since S298A mutant is still reactive Akt phospho-substrate specific 
antibody (Figure 1). Taken together, these observations suggest that S298 is a critical 
component linking Eya1 to PI3K/Akt signaling.
SUMOylation inhibits Eya1 transcription activity
Results here suggest that SUMOylation inhibits Eya1 transcription. A systemic mutagenesis 
analysis indicates that Eya1 is SUMOylated at K43 and K146 sites (Figure 3). Eya1 mutant 
variants that lack these sites are significantly more potent than wild type Eya1 to activate 
transcription reporters and downstream endogenous target gene expression (Figure 3 and 
S3). In addition, reduction of Eya1 SUMOylation by Senp2 also potentiates Eya1 
transcription activity. Conversely, Eya1 and SUMO1 fused proteins, which mimic 
SUMOylated Eya1, significantly inhibited transcription reporter gene activities.
Paradoxically, murine Sumo1 heterozygous deletion augments Eya1+/− cleft palate 
phenotype.18 suggesting that development of the hard palate depends on both Eya1 and 
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SUMOylation. Deletion of Sumo1 may result in a global reduction of SUMOylation level of 
all substrates. Therefore, it is possible that other SUMOylated proteins in addition to Eya1 
contribute to the cleft palate phenotype.18 In contrast to the genetic approach, our study was 
designed to address specifically the impact of SUMOylation on Eya1 without affecting other 
SUMO-substrates. These experimental differences may contribute to the discrepancy. It is 
also worth noting that cleft palate but not renal phenotype was reported in the Sumo1 and 
Eya1 compound heterozygous.18 This is important because renal development is particularly 
sensitive to Eya1 level.29 It is therefore possible that the functional relationship between 
Eya1 and SUMOylation maybe cell type-dependent.
PI3K/Akt signaling inhibits Eya1 SUMOylation
We report here that PI3K/Akt regulates Eya1 activity via a novel SUMOylation mechanism 
(Figure 4). Activation of the PI3K/Akt signal pathway represses Eya1 SUMOylation level, 
which is in part mediated through S298 residue. A critical remaining question is how Eya1 
phosphorylation inhibits its SUMOylation. Early studies reveal that Dach1 and Six1 are 
biochemical and genetic partners of Eya1.10, 45 Interestingly, Ubc9, a critical SUMO-
conjugating enzyme was identified in the yeast two-hybrid screening that directly interacts 
with Dach1.46 Many candidate Eya1 interacting partners have since been identified but their 
function in Eya1 SUMOylation has not been explored yet.47 It is conceivable that 
SUMOylation machinery might be recruited through Eya1 interacting partners, such as 
Dach1; and such recruitment could be regulated by PI3K/Akt signaling.
The PI3K/Akt signal pathway plays a prominent role is physiology and diseases. To the best 
of our knowledge, this is the first example that it hyperactiviates an oncoprotein through a 
phosphorylation-dependent SUMOyation mechanism. Intriguingly, Akt1 is also 
SUMOylated; and SUMOylation promotes Akt1 kinase activity.48 Taken together, these 
observations suggest that crosstalk between the PI3K/Akt signal pathway and SUMOylation 
mechanism is likely a critical aspect of cancer biology.
Materials and Methods
Mouse strains
All animal studies were performed according to protocols reviewed and approved by the 
Institutional Animal Care and Use Committee at the Children’s Hospital Boston. 
Development of heterozygous Eya1 mouse strains was described previously6. Akt1 
heterozygous mice were purchased from Jackson Laboratory (Stock number: 004912), 
donated by Morris Birnbaum31. PCR genotyping was performed as described 
previously6, 31. Akt1 and Eya1 compound heterozygous mutants, derived from an Eya1+/− 
and Akt1+/− cross, were used to generate appropriate control and experimental groups. All 
mice were maintained on C57BL6, 129svj, or CD-1 mixed genetic backgrounds. P0 pups 
were collected and weighed. Kidneys were dissected and weighed. Bodies and kidneys were 
imaged on an Olympus DP71 digital camera.
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Plasmids and reagents
Six1 reporter constructs, SE1/luc and SE2/luc, were described previously.1, 7 The reporters 
contained Six1 binding elements (annealing by 5’-TCG AGT AAT CCG AGA CCC TGT 
AAA TTG ATA CGG AGT AAT TCG ATA TCG A-3’, 5 ’-AGC TCA TTA GGC TCT 
GGG ACA TTT AAC TAT GCC TCA TTA AGC TAT AGC T-3’) with basal promoters 
with minimal and high activities, respectively. The Fgf8 promoter reporter was described 
previously.7 Akt1 expression constructs and siAkt SMARTpool reagents (Thermo Scientific 
Dharmacon) were obtained from Dr. Rosalyn Adam (Boston Children's Hospital). The 
lentiviral constructs of Eya1 overexpression and the shRNA were subcloned into 
pLentiCMV (from Dr. Lan Xu, UMass Med, Worcester) and pLKO.1 vector, respectively.
Cell lines
HEK293, BT549 and MDA157 (from Dr. Joan Brugge, Harvard Medical School) and 
SUM14949 (from Dr. Charlotte Kuperwasser, Tufts University), were maintained using 
standard procedures. The stable pools of EYA1 knockdown and Eya1 rescue cells were 
generated with EYA1 shRNA or Eya1 lentiviral particles and selected with puromycin (2 
µg/ml) or blasticidin (10 µg/ml), respectively. Cell proliferation and viability were measured 
by either cell number counts or using MTT (3-(4,5-Dimethylthiazol-2-yl) - 2,5 - 
diphenyltetrazolium bromide) assays. For γ-irradiation, cells were treated with a single dose 
of gamma rays from Cesium-137 (Boston Children’s Hospital), and allowed to recover at 
37°C for the indicated times before analysis.
Real-time quantitative PCR
Real-time quantitative PCR was performed using VeriQuest™ SYBR® Green (Affimetrix) 
on an ABI StepOnePlus (Applied Biosystems). PCR primers were 5’-ACT TAC CAG CTT 
CAA GAA CCG-3' and 5'-ATT TCC CAT CTG AAC CTC GAC-3' for EYA1; 5’-CAC 
AGC CCA CTG GTC CTC AAG AGG-3’ and 5’- TGT TTC AAC TGT TCT CGT CGT 
TTC C-3’ for c-MYC; 5’- GCC CTC TGT GCC ACA GAT GTG AAG-3’ and 5’-GTT CTG 
CTG GGC CTG GCG CAG GCT-3’ for CYCLIN D1; 5’-CGC TGA GCT GCC TGC TGT 
TGC-3’ and 5’-GGT AGG TCC GGA TGA GGC GGC-3’ for FGF8; 5’-GCC TCA AGA 
TCA TCA GCA AT-3’ and 5’-TTC AGC TCA GGG ATG ACC TT-3’ for GAPDH.
Cell migration and soft agar assays
A total of 5×104 cells in 100 µl of serum free medium were placed in the inserts of Costar 
Transwell® (8.0 µm pore size, Corning). The bottom chamber was filled with complete 
medium containing 20% fetal bovine serum. After incubation at 37°C, 5% CO2 for 2 – 4 
hours, slowly migrating cells on the top layer of the Transwell were removed using cotton 
swabs. The cells remaining that had migrated and attached to the bottom layer of Transwell 
inserts were fixed with 100% methanol and stained with 0.1% crystal violet. Total cell 
number was counted under an Olympus SZX16 microscope and imaged using a DP71 
digital camera.
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Luciferase assay
Luciferase assays were performed using Dual-Luciferase assay system (Promega) in 
HEK293 cells) and reporter activities were measured using a Wallac 1420 Multilabel 
Counter (Perkin Elmer luminometer) and normalized with pRL-TK renilla.
Immunoprecipitation and in vitro kinase assay
The expression plasmids were transfected 293 cells by Lipofectamine 2000 (Invitrogen). 
The cells were lysed with IP buffer (1.0% Triton X-100, 50 mM Tris-HCl pH 7.6, 300 mM 
NaCl, 1 mM EDTA, 2.5 mM Sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM 
Na3VO4, 5 mM NaF, 1 mM PMSF and protease inhibitor cocktail). Immunoprecipitation 
were done using standard protocol. For in vitro kinase assay, Flag-tagged proteins were 
immunoprecipitated by anti-Flag affinity gel (Sigma-Aldrich) and eluted by 3XFlag peptide 
(150 ng/µl in 50 mM Tris-HCl pH7.6, 150 mM NaCl). Eya1 and S298A mutant proteins and 
recombinant active AKT1 (R&D Systems) were mixed and incubated in kinase reaction 
buffer (5 mM MOPS pH 7.2, 2.5 mM beta-glycerophosphate, 5 mM MgCl2, 1mM EGTA, 
0.4 mM EDTA, 0.4% glycerol, 5 µM ATP and 5 µCi gamma-[32P]-ATP) at room 
temperature for 30 min. Reaction products were subjected to SDS-PAGE and transferred to 
PVDF membrane. The phosphorylation of Eya1 was detected by exposing to X-Ray film. 
Eya1 protein levels were examined by protein immunoblot using an anti-Flag-HRP 
antibody.
Statistics
Data analysis was performed with MedCalc software. Paired Student’s t test was used to 
determine the differences between groups. Data are presented as mean ± SEM (n = 3). P 
values less than 0.05 were considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Akt1 interacts with and phosphorylates Eya1
(A) A conserved substrate consensus site of Akt kinase identified in Eya1.
(B and C) Immunoprecipitation (IP) using antibodies against either a pan-AKT (AKT) (B), 
EYA1 (C) or control IgG from BT549 cell lysates, and resultants were immunoblotted (IB) 
using indicated antibodies.
(D and E) Co-IP of full-length mouse Akt1 and Flag-tagged Eya1 (Flag/Eya1) fragments 
from transfected HEK293 cells. Results are summarized in E. *, inconclusive.
(F) Immunoprecipitates (Flag/Eya1 or Flag/S298A) were incubated with recombinant AKT1 
(r-AKT1) in an in vitro kinase assay with γ-[32P]-ATP. Top panel, autoradiography; bottom 
panel, protein immunoblot using a Flag-specific antibody.
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(G) Immunoprecipitates from the phospho-specific Akt substrate antibody (p-sub) were 
probed using indicated antibodies. Flag/S298A, an Eya1 serine 298 to alanine mutation; 
myr-HA/Akt1, myristoylated HA-tagged Akt1, GAPDH was used as loading control.
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Figure 2. Akt1 induces Eya1 transcription activity
(A) HEK293 cells were transiently transfected with the Flag/Eya1 and/or HA/Akt1 
expression constructs and analyzed by indirect immunocytochemistry using a Flag-antibody 
(green, 1), HA- antibody (Red, 2) and counter-stained with DAPI (blue). 3, a merged image 
of 1 and 2.
(B–C) Combinations of Akt1, Flag/Eya1 and Myc/Six1 were co-expressed in HEK293 cells. 
co-IP and IB were done using indicated antibodies.
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(D) A transient transcription reporter assay using a Six1/Eya1-dependent reporter (SE1/luc), 
which was co-expressed with combinations of indicated expression constructs. Relative fold 
changes were calculated using basal and Renilla controls (mean ± SEM, n=5).
(E) Schematic diagram of regulation of Eya1 activities. Resting state Eya1 has low 
transcription activity (low, in a dash box). Akt1 increases Eya1 transcription (HIGH) in part 
through the conserved S298 phosphorylation (p) site.
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Figure 3. SUMOylation represses Eya1 transcription activity
(A–B) Immunoprecipitation (IP) of endogenous EYA1 (A) or SUMO1 (B) from HEK293 
cells and immunobloted (IB) using indicated antibodies. IgG, negative control.
(C) Flag/Eya1 and HA/Sumo1 were transiently expressed in HEK293 cells with SenP2 or a 
control (con). IP and IB were performed using indicated antibodies.
(D) Combinations of lysine (K) 43, 146 and 459 to arginine (R) Eya1 mutatn variants were 
used to map Eya1 SUMOylation sites in an IP and IB assay. Number 1 and 2 indicate single 
and double SUMOylated Eya1, respectively.
(E–G) Reporter assays indicated that SUMOylation represses Eya1 transcription activity. 
The Six1/Eya1-dependent reporter (SE1/luc) was co-transfected with indicated constructs 
and the luciferase reporter activity was measure at 48 hours (n=3). S1-Eya1, Eya1-S1: fusion 
of SUMO1 to Eya1 at N- and C-terminus, respectively.
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Figure 4. Akt1 inhibits Eya1 SUMOylation
(A–C) Inhibition of PI3K/Akt signaling with an inhibitor LY294002 (25 µM, 2 h, A and B) 
or AKT siRNA oligo sets (C, targeting all three AKT1/2/3 isoforms, Dharmacon) enhanced 
endogenous EYA1 (A) and Flag/Eya1 (B and C) SUMOylation levels. IP and IB were 
performed using indicated antibodies.
(D) S298A mutant had enhanced SUMOylation level.
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(E and F) Constitutively active myr-HA/Akt1 suppressed SUMOylation of wild type Eya1 
(E) but not S298A mutant (F). Flag/Eya1, Flag/S298A and HA/Sumo1 were transiently 
expressed in HEK293 cells with gradient amount of myr-HA/Akt1.
(G) Akt1 induced Eya1 transcription activity via inhibition of Eya1 SUMOylation. The 
Six1/Eya1-dependent reporter (SE1/luc) was co-transfected with indicated constructs and 
the luciferase reporter activity was measure at 48 hours. Relative fold changes were 
calculated using basal and Renilla controls (mean ± SEM, n=3). ns, not significant; KS/RA, 
K43R/K164R/S298A triple mutation.
Sun et al. Page 22
Oncogene. Author manuscript; available in PMC 2015 November 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 5. Genotoxic stress decreases Eya1 SUMOylation via the PI3K/Akt pathway
(A–C) HEK293 cells, transfected with Flag/Eya1 and HA/Sumo1, were γ-irradiated with the 
indicated doses and allowed to recover for indicated time prior to IP and IB assays. 
Densitometry for quantification were presented in B and C. LY, LY294002.
(D–E) Flag/Eya1- and HA/Sumo1-expressing HEK293 cells were treated with camptothecin 
(CPT, 10 µM, 30 min) or DMSO (D) in the presence or absence of siAKT (E) prior to the IP 
and IB analysis using indicated antibodies.
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Figure 6. EYA1 and PI3K/Akt synergistically promote breast cancer cell survival
(A–B) Growth rate of stable clones of BT549 breast cancer cells infected with EYA1-
specific shRNAs (shEYA1, 1–4) or control (shCon) lentiviral particles. Cell number was 
quantified after a 3-day culture (A, n=3), or over a 6-day time course (B, n=6). Values are 
expressed as mean ± SEM. *, p<0.01.
(C) EYA1 knockdown attenuates growth of all four lines of breast cancer cells. The indicated 
cells were infected with either control (shCon) or EYA1-specific (shEYA1-2) shRNA 
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lentiviral particles, and cell number was quantified after 5 days (BT549, MDA157, 
SUM149) or 6 days (MDA157).
(D–E) Increased sensitivity of EYA1-silenced BT549 breast cancer cells to genotoxic agent 
camptothecin (CPT) or PI3K/Akt inhibition (LY294002). Equivalent numbers of control 
(shCon, solid line) and EYA1-silenced (shEya1-1, 2, 4, dotted lines) cells were treated with 
either LY294002 or CPT for 24 hours. Relative survival rates were compared with mock 
transfected cells (DMSO) (mean ± SEM, n=6). *, p<0.01.
(F) Rescue of EYA1-silenced BT549 cells by wild type mouse Eya1. Equal number of cells 
was treated with CPT as indicated. Surviving cells were counted 24 h later (n=6). *, EYA1 
vs shCon, p<0.01; **, shEYA1 vs shEYA1+Eya1, p< 0.001.
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Figure 7. Eya1-mediated cell motility depends on the Akt phosphorylation site
(A–B) Migration of control BT549 cells (shCon, 1), EYA1-silenced (shEYA1-2), and the 
corresponding cells rescued with wild type mouse Flag/Eya1, were assayed over a 2h period. 
Quantified results were shown in B (mean ± SEM, n=3).
(C) Several murine Eya1 variants were stably expressed in EYA1-silenced BT549 cells. The 
upper bar graph, real-time quantitative PCR assay; the bottom blots, immunoblots of total 
cell lysate using antibodies specific to Flag (for murine Eya1 variants) and GAPDH (internal 
loading control). Con, scrambled shRNA; vec, empty expression construct; Eya1, wild type 
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mouse Eya1; D327A, phosphatase-dead mutation; S298A, a phosphorylation-defective 
mutation. All rescue constructs were Flag tagged.
(D) Migration rate of stable BT549-derived cell lines was examined over a 4 h period. 
Number of cells was counted and quantitatively analyzed (mean ± SEM, n=3).
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